KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Subcutaneous versus intravenous nivolumab for renal cell carcinoma. PMID 39288844 · Ann Oncol · 2025-Jan The study is a Phase III randomized trial with a drug intervention in oncology, but the primary and key secondary endpoints are pharmacokinetic parameters and objective response rate, respectively. There is no mention of a time-to-event efficacy endpoint such as OS, PFS, DFS, or HR in the provided abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). PMID 39249591 · Adv Ther · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo. PMID 39243988 · Brain Behav Immun · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents. PMID 39243794 · Lancet Infect Dis · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration. PMID 39230186 · Clin Pharmacol Drug Dev · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study. PMID 39225890 · AIDS Behav · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. PMID 39205396 · Perit Dial Int · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. PMID 39178993 · J Allergy Clin Immunol · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. PMID 39133306 · Eur J Nucl Med Mol Imaging · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The treatment effect across ASPECTS in acute ischemic stroke: Analysis from the AcT trial. PMID 39086232 · Int J Stroke · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adenoma detection rate and tolerability of 2 ultra-low-volume bowel preparations in screening: a noninferiority randomized controlled trial. PMID 39069266 · Gastrointest Endosc · 2025-Jan The study is an oncology-related randomized trial but fails two key eligibility criteria: (1) The intervention is not a drug-containing anti-cancer treatment; it compares bowel cleansing preparations for colonoscopy in a screening program. (2) The primary endpoint is adenoma detection rate, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it is not eligible for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide. PMID 39009085 · J Hepatol · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation. PMID 38992106 · Eur Radiol · 2025-Jan The study is a randomized, multicenter prospective diagnostic accuracy trial comparing imaging modalities for hepatocellular carcinoma (oncology, human, randomized). However, it is excluded because: 1) it is not a Phase III/IIIb or definitive Phase II/III randomized trial (no phase is specified, and the design is a diagnostic accuracy study, not a therapeutic efficacy trial), 2) there is no drug-containing intervention (the intervention is locoregional therapies, not a drug regimen), and 3) there is no time-to-event efficacy endpoint (the primary outcome is diagnostic performance metrics like sensitivity, specificity, and AUC, not survival outcomes). Therefore, it does not meet the inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis. PMID 38857909 · J Gynecol Oncol · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis. PMID 38857908 · J Gynecol Oncol · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial. PMID 38682328 · Expert Opin Drug Saf · 2025-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunocyte profiling changes in patients received epidural versus intravenous analgesia after pancreatectomy: A randomized controlled trial. PMID 38494360 · J Formos Med Assoc · 2025-Jan The trial is randomized and reports time-to-event efficacy endpoints (PFS, OS). However, the intervention compares analgesia techniques (epidural vs. IV patient-controlled analgesia), which is a non-drug-only intervention. It does not involve a systemic drug intervention (e.g., chemotherapy, targeted therapy, immunotherapy) as required for eligibility. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hyperthermic intraperitoneal chemotherapy plus SOX chemotherapy versus SOX chemotherapy alone in patients with gastric cancer and peritoneal metastasis: a phase II randomized clinical trial. PMID 40115934 · J Gastrointest Oncol · 2025-Feb-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Partial pressure of oxygen control versus modified inflation-deflation method in identifying intersegmental plane during anatomical sublobectomy: a prospective, randomized, controlled trial. PMID 40083504 · J Thorac Dis · 2025-Feb-28 Study is a randomized trial in oncology (NSCLC surgical technique) but fails key eligibility criteria: not a drug intervention trial (compares PaO2 control vs. modified inflation-deflation methods for ISP identification), not phase III/definitive (phase not specified, appears to be a surgical technique comparison trial), and lacks time-to-event efficacy endpoint (primary outcome is time to ISP appearance, not OS/PFS/DFS etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib. PMID 40075694 · Cancers (Basel) · 2025-Feb-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up. PMID 40022029 · BMC Cancer · 2025-Feb-28 The record describes a randomized trial of radiotherapy in breast cancer, which is oncological and human, with a time-to-event endpoint (ipsilateral breast tumor recurrence). However, the intervention is radiotherapy, not a drug. The trial is not a Phase III/IIIb or Phase II/III drug trial. The study is a secondary analysis investigating a biomarker's predictive value, not a primary efficacy report of a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Comparison of Statistical Methods for Time-To-Event Analyses in Randomized Controlled Trials Under Non-Proportional Hazards. PMID 39973243 · Stat Med · 2025-Feb-28 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Longitudinal circulating tumor DNA monitoring in predicting response to short-course radiotherapy followed by neoadjuvant chemotherapy and camrelizumab in locally advanced rectal cancer: data from a Phase Ⅲ clinical trial (UNION). PMID 39755361 · Cancer Lett · 2025-Feb-28 The study is a Phase III RCT with a drug intervention, but the primary endpoint is pathological complete response (pCR), a binary outcome, not a time-to-event endpoint. No OS, PFS, or other time-to-event efficacy data are reported in the provided information.
L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multi-centre, participant-blinded, randomized, 3-year study to compare the efficacy of Virtual Surgical Planning (VSP) to Freehand Surgery (FHS) on bony union and quality of life outcomes for mandibular reconstruction with fibular and scapular free flaps: study protocol for a randomized phase II/III trial. PMID 40016641 · BMC Cancer · 2025-Feb-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial. PMID 40016311 · Sci Rep · 2025-Feb-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens. PMID 40016280 · Sci Rep · 2025-Feb-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]. PMID 39837003 · Vaccine · 2025-Feb-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma. PMID 39630057 · Blood · 2025-Feb-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Overcoming barriers to implementation of patient engagement in clinical trials: feasibility testing of an embedded study. PMID 40012063 · Res Involv Engagem · 2025-Feb-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health - study protocol paper for a phase III multicentre, open-label randomised controlled trial. PMID 40010843 · BMJ Open · 2025-Feb-26 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Little Journey: a phase III randomised controlled trial of a psychological preparation and education smartphone application for management of paediatric perioperative anxiety compared with standard care in children undergoing ambulatory surgery - study protocol. PMID 40010809 · BMJ Open · 2025-Feb-26 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. PMID 40010775 · J Immunother Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. PMID 40010771 · J Immunother Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial. PMID 40001034 · BMC Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. PMID 40001000 · BMC Musculoskelet Disord · 2025-Feb-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Digital Therapeutics-Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial. PMID 39999435 · JMIR Mhealth Uhealth · 2025-Feb-25 The study is a randomized controlled trial in human lung cancer survivors, but it evaluates a non-drug digital therapeutics-based telerehabilitation intervention and its primary endpoints are cardiopulmonary fitness (e.g., VO2 peak) and quality of life, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the drug intervention or time-to-event endpoint criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the uptake of the core outcome set in randomized controlled trials for coronary artery disease: a trial registry analysis. PMID 39994760 · Trials · 2025-Feb-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial. PMID 39864364 · Eur J Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial. PMID 39864363 · Eur J Cancer · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial. PMID 39846936 · J Am Coll Cardiol · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. PMID 39826197 · Eur J Cancer · 2025-Feb-25 The record is a pooled analysis across age subgroups from three randomized trials, not the primary result report of a single Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. PMID 39798264 · Eur J Cancer · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. PMID 39671272 · JAMA · 2025-Feb-25 The study is a randomized, double-blind, Phase III oncology trial with a drug intervention (camrelizumab). However, its primary endpoint is pathological complete response (pCR), which is a binary endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) that would be analyzed with Kaplan-Meier methods or report a hazard ratio. The deterministic review correctly identified this as 'no_time_to_event_signal'. Therefore, it does not meet the requirement for a time-to-event primary or key secondary endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. PMID 39626287 · Blood Adv · 2025-Feb-25 The study is an oncology randomized Phase 3 trial with drug intervention and original results, but the reported analysis is an ad hoc investigation of peripheral neuropathy symptom resolution and quality of life. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or associated Kaplan-Meier/HR statistics. Therefore, it is ineligible for the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial. PMID 38858097 · Stroke Vasc Neurol · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial. PMID 39993822 · BMJ · 2025-Feb-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial. PMID 39523543 · Clin Infect Dis · 2025-Feb-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: a prospective randomized controlled trial. PMID 39985582 · Support Care Cancer · 2025-Feb-22 This is a randomized controlled trial of a non-drug intervention (exercise) in pediatric ALL survivors. While it involves patients with a human malignant neoplasm and is a prospective randomized trial, it does not meet the core eligibility criteria: 1) It is not a Phase III/IIIb or Phase II/III trial (no phase specified in metadata, likely an early-phase or single-center trial), and 2) The primary efficacy endpoints are not time-to-event (e.g., OS, PFS) but are functional, morphological, and patient-reported outcomes measured at baseline and post-intervention. The drug intervention criterion is met only peripherally as patients are 'cancer survivors' who have completed chemotherapy, but the trial itself tests an exercise intervention, not a drug therapy. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. PMID 39919773 · Lancet · 2025-Feb-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Efficacy and Safety of Pelubiprofen in the Treatment of Acute Upper Respiratory Tract Infection: A Multicenter, Randomized, Double-Blind, Non-Inferiority Phase III Clinical Trial Compared to Loxoprofen. PMID 40094866 · J Clin Med · 2025-Feb-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -